Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients

被引:29
|
作者
Hodel, Eva Maria Staehli [1 ]
Guidi, Monia [2 ,3 ,4 ]
Zanolari, Boris [3 ,4 ]
Mercier, Thomas [3 ,4 ]
Duong, Socheat [5 ]
Kabanywanyi, Abdunoor M. [6 ]
Ariey, Frederic [7 ]
Buclin, Thierry [3 ,4 ]
Beck, Hans-Peter [1 ]
Decosterd, Laurent A. [3 ,4 ]
Olliaro, Piero [8 ]
Genton, Blaise [1 ,9 ,10 ]
Csajka, Chantal [2 ,3 ,4 ]
机构
[1] Univ Basel, Swiss Trop & Publ Hlth Inst, Basel, Switzerland
[2] Univ Lausanne, Univ Geneva, Sch Pharmaceut Sci, Geneva, Switzerland
[3] CHU Vaudois, Dept Labs, Div Clin Pharmacol & Toxicol, CH-1011 Lausanne, Switzerland
[4] Univ Lausanne, Lausanne, Switzerland
[5] Natl Ctr Parasitol Entomol & Malaria Control, Phnom Penh, Cambodia
[6] Ifakara Hlth Inst, Dar Es Salaam, Tanzania
[7] Inst Pasteur Cambodia, Mol Epidemiol Unit, Phnom Penh, Cambodia
[8] UNICEF UNDP World Bank WHO Special Programme Res, Geneva, Switzerland
[9] Univ Lausanne Hosp, Dept Ambulatory Care & Community Med, Lausanne, Switzerland
[10] Univ Lausanne Hosp, Div Infect Dis, Lausanne, Switzerland
基金
瑞士国家科学基金会;
关键词
Malaria; Population pharmacokinetics; Artemisinin-based combination therapy; Tanzania; Cambodia; Piperaquine; Mefloquine; Lumefantrine; Artemether; Nonlinear mixed-effects modelling; PLASMODIUM-FALCIPARUM MALARIA; SINGLE NUCLEOTIDE POLYMORPHISMS; ARTEMISININ-RESISTANT MALARIA; SULFADOXINE-PYRIMETHAMINE; UNCOMPLICATED MALARIA; COMBINATION TREATMENT; PLASMA-CONCENTRATIONS; THERAPEUTIC RESPONSE; PREGNANT-WOMEN; ANTIMALARIAL;
D O I
10.1186/1475-2875-12-235
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Inter-individual variability in plasma concentration-time profiles might contribute to differences in anti-malarial treatment response. This study investigated the pharmacokinetics of three different forms of artemisinin combination therapy (ACT) in Tanzania and Cambodia to quantify and identify potential sources of variability. Methods: Drug concentrations were measured in 143 patients in Tanzania (artemether, dihydroartemisinin, lumefantrine and desbutyl-lumefantrine), and in 63 (artesunate, dihydroartemisinin and mefloquine) and 60 (dihydroartemisinin and piperaquine) patients in Cambodia. Inter-and intra-individual variabilities in the pharmacokinetic parameters were assessed and the contribution of demographic and other covariates was quantified using a nonlinear mixed-effects modelling approach (NONMEM (R)). Results: A one-compartment model with first-order absorption from the gastrointestinal tract fitted the data for all drugs except piperaquine (two-compartment). Inter-individual variability in concentration exposure was about 40% and 12% for mefloquine. From all the covariates tested, only body weight (for all antimalarials) and concomitant treatment (for artemether only) showed a significant influence on these drugs' pharmacokinetic profiles. Artesunate and dihydroartemisinin could not be studied in the Cambodian patients due to insufficient data-points. Modeled lumefantrine kinetics showed that the target day 7 concentrations may not be achieved in a substantial proportion of patients. Conclusion: The marked variability in the disposition of different forms of ACT remained largely unexplained by the available covariates. Dosing on body weight appears justified. The concomitance of unregulated drug use (residual levels found on admission) and sub-optimal exposure (variability) could generate low plasma levels that contribute to selecting for drug-resistant parasites.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] Population Pharmacokinetics and Clinical Response for Artemether-Lumefantrine in Pregnant and Nonpregnant Women with Uncomplicated Plasmodium falciparum Malaria in Tanzania
    Mosha, Dominic
    Guidi, Monia
    Mwingira, Felista
    Abdulla, Salim
    Mercier, Thomas
    Decosterd, Laurent Arthur
    Csajka, Chantal
    Genton, Blaise
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (08) : 4583 - 4592
  • [22] Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications
    Hoglund, Richard M.
    Byakika-Kibwika, Pauline
    Lamorde, Mohammed
    Merry, Concepta
    Ashton, Michael
    Hanpithakpong, Warunee
    Day, Nicholas P. J.
    White, Nicholas J.
    Abelo, Angela
    Tarning, Joel
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 79 (04) : 636 - 649
  • [23] Artemether-lumefantrine: an oral antimalarial for uncomplicated malaria in children
    Adjei, George O.
    Goka, Bamenla Q.
    Binka, Fred
    Kurtzhals, Jorgen A. L.
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2009, 7 (06) : 669 - 681
  • [24] Longitudinal Outcomes in a Cohort of Ugandan Children Randomized to Artemether-Lumefantrine Versus Dihydroartemisinin-Piperaquine for the Treatment of Malaria
    Wanzira, Humphrey
    Kakuru, Abel
    Arinaitwe, Emmanuel
    Bigira, Victor
    Muhindo, Mary K.
    Conrad, Melissa
    Rosenthal, Philip J.
    Kamya, Moses R.
    Tappero, Jordan W.
    Dorsey, Grant
    CLINICAL INFECTIOUS DISEASES, 2014, 59 (04) : 509 - 516
  • [25] Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Falciparum Malaria: A Longitudinal, Randomized Trial in Young Ugandan Children
    Arinaitwe, Emmanuel
    Sandison, Taylor G.
    Wanzira, Humphrey
    Kakuru, Abel
    Homsy, Jaco
    Kalamya, Julius
    Kamya, Moses R.
    Vora, Neil
    Greenhouse, Bryan
    Rosenthal, Philip J.
    Tappero, Jordan
    Dorsey, Grant
    CLINICAL INFECTIOUS DISEASES, 2009, 49 (11) : 1629 - 1637
  • [26] A randomized trial of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali
    Dama, Souleymane
    Niangaly, Hamidou
    Djimde, Moussa
    Sagara, Issaka
    Guindo, Cheick Oumar
    Zeguime, Amatigue
    Dara, Antoine
    Djimde, Abdoulaye A.
    Doumbo, Ogobara K.
    MALARIA JOURNAL, 2018, 17
  • [27] Acceptability and comparative efficacy of artemether-lumefantrine vs. dihydroartemisinin/piperaquine in Kenyan children with uncomplicated falciparum malaria
    Onyango, K. O.
    Ongecha, J. M.
    Juma, E.
    Otieno, G. A.
    Obonyo, C.
    Otieno, L.
    Perkins, D. J.
    Akhwale, W.
    Ogutu, B.
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2011, 16 : 110 - 110
  • [28] A randomized trial of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated malaria among children in western Kenya
    Aarti Agarwal
    Meredith McMorrow
    Peter Onyango
    Kephas Otieno
    Christopher Odero
    John Williamson
    Simon Kariuki
    Stephen Patrick Kachur
    Laurence Slutsker
    Meghna Desai
    Malaria Journal, 12
  • [29] A randomized trial of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated malaria among children in western Kenya
    Agarwal, Aarti
    McMorrow, Meredith
    Onyango, Peter
    Otieno, Kephas
    Odero, Christopher
    Williamson, John
    Kariuki, Simon
    Kachur, Stephen Patrick
    Slutsker, Laurence
    Desai, Meghna
    MALARIA JOURNAL, 2013, 12
  • [30] Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Malaria in Children in Zaire and Uige Provinces, Angola
    Plucinski, Mateusz M.
    Talundzic, Eldin
    Morton, Lindsay
    Dimbu, Pedro Rafael
    Macaia, Aleixo Panzo
    Fortes, Filomeno
    Goldman, Ira
    Lucchi, Naomi
    Stennies, Gail
    MacArthur, John R.
    Udhayakumar, Venkatachalam
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (01) : 437 - 443